Innovations in Therapeutic Approach for Cystic Fibrosis, 2018 Report - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Innovations in Therapeutic Approach for Cystic Fibrosis” report has been added to ResearchAndMarkets.com’s offering.
This Genetic Technology TOE depicts life sciences trends across cystic fibrosis. First-in class mRNA therapeutics with targeted delivery, novel cell types, lentiviral gene therapy, and RNA vaccines, among other therapies are profiled. Clinical trials of RNA vaccines for the cancer treatment are also depicted.
The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.
Key Topics Covered:
Recent Advances in Development of Novel Treatments for Cystic FibrosisA First-in Class mRNA Therapeutic With Targeted Delivery Novel Cell Type that Can Revolutionize Cystic Fibrosis Treatment Collaborative Development of Lentiviral Gene Therapy Treating Pulmonary Exacerbations in Cystic Fibrosis patients
Clinical Trial Analysis and Key ContactsClinical Trial Analysis of RNA Vaccines for the Treatment of Cancer Key Contacts For more information about this report visit https://www.researchandmarkets.com/research/7w4h4z/innovations_in?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005765/en/
Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Respiratory Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/19/2018 03:27 PM/DISC: 09/19/2018 03:27 PM